ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data
ORIC Pharmaceuticals' shares dropped 22% after Johnson & Johnson presented early data for its rival prostate cancer drug, JNJ-6143. JNJ-6143 showed a 75% response rate in a small Phase 1 study. ORIC's own drug, rinzimetostat, is in a Phase 3 trial. ORIC has $388 million in cash, expected to last into 2H 2028, and a market cap of about $1.1 billion.
How this was made
The 30-second read
Why it matters
The announcement creates immediate competitive pressure on ORIC's lead asset, driving a sharp share decline.
Market read
ORIC's stock move reflects heightened competitive risk in the prostate cancer therapeutic space.
What to watch
ORIC's cash runway through 2028 and potential partnership opportunities could mitigate downside.
Background
Johnson & Johnson disclosed early Phase 1 results for its experimental prostate cancer drug JNJ-6143 at the ESMO Congress, prompting a market reaction to competitor ORIC.
Ticker impact
ORIC shares dropped 22% after Johnson & Johnson presented early prostate cancer data that threatens ORIC's lead drug rinzimetostat.
likely further pressure as investors price in competitive risk to rinzimetostat.
The new J&J Phase 1 results suggest a potent alternative, and ORIC's drug is still in Phase 3, prompting a sharp sell-off.
Market effects
Highlights competitive risk in the prostate cancer biotech niche, may affect peer valuations.
Primarily impacts US-listed biotech stocks.
Limited to biotech sector; no broad market effect.
Counterpoint
If J&J's data does not translate to later‑stage efficacy, ORIC could rebound on its Phase 3 readout.
Key entities
- companyORIC Pharmaceuticals
Biotech developing rinzimetostat, Phase 3 trial.
- companyJohnson & Johnson
Presented early data for rival prostate cancer drug JNJ-6143.

